Try our mobile app

Switch to company model in classical logic    *

General information

Country: SPAIN

Sector: Drug Manufacturers — General

Grifols S.A. develops, manufactures, and markets plasma derivatives, IV Therapy, enteral nutrition, diagnostic systems, and medical materials.
Website: grifols.com



Growth: Pretty weak revenue growth rate 6.9%, there is slowdown compared to average historical growth rates 7.0%. The revenue growth dynamics is moderately stable Site traffic for the last 3 months showed a change of +28.8%

Profitability: LTM EBITDA margin is positive, +26.2%. On average the margin is improving unsteadily. Gross margin is high, +43.0%. In the last quarter the company beat the estimated EPS, +3.7%. The company was ahead of estimated EPS in 75% of quarters (showing a gain of +$0.02 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -11.8% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 16.6% higher than minimum and 66.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.9x by EV / Sales multiple , the company can be 29.6% overvalued

Key Financials (Download financials)

Ticker: GRFS
Share price, USD:  (+1.8%)6.38
year average price 8.75  


year start price 7.46 2023-04-28

max close price 11.56 2023-12-29

min close price 5.47 2024-03-06

current price 6.38 2024-04-26
Common stocks: 2 392 074 100

Dividend Yield:  0.0%
FCF Yield LTM: -11.8%
EV / LTM EBITDA: 16.0x
EV / EBITDA annualized: 15.9x
Last revenue growth (y/y):  6.9%
Last growth of EBITDA (y/y):  66.3%
Historical revenue growth:  7.0%
Historical growth of EBITDA:  7.4%
EV / Sales: 4.2x
Margin (EBITDA LTM / Revenue): 26.2%
Fundamental value created in LTM:
Market Cap ($m): 15 261
Net Debt ($m): 10 685
EV (Enterprise Value): 25 946
Price to Book: 2.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2024-04-14Reuters

Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper

2024-04-10Reuters

Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake

2024-03-06Reuters

Grifols shares drop to 12-year low after new Gotham City Research report

2024-03-06Reuters

Grifols shares drop 15% after new Gotham City Research report

2024-03-01Reuters

Grifols says due diligence done, Shanghai RAAS stake sale to go ahead

2024-02-29Proactive Investors

Grifols hushed on Gotham City short-sell attack during annual results

2024-02-20Proactive Investors

Gotham City Research once again questions Grifols

2024-02-20Proactive Investors

Gotham City Research renews short-sell attack on Grifols

2024-02-20Reuters

Gotham City issues new report on Grifols, maintains questions over accounting practices

2024-02-14Zacks Investment Research

GRFS or ZTS: Which Is the Better Value Stock Right Now?
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q4 2023 q3 2023 q2 2022 q4 2022 q2 2021 q2
date 2023-12-31 2023-09-30 2023-06-30 2022-12-31 2022-06-30 2021-06-30
symbol GRFS GRFS GRFS GRFS GRFS GRFS
reportedCurrency EUR EUR EUR USD EUR EUR
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-04-19 2023-09-30 2023-06-30 2023-04-18 2022-06-30 2021-06-30
acceptedDate 2024-04-19 16:30:06 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-04-18 09:25:44 2022-06-29 20:00:00 2021-06-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2021.000
period Q4 Q3 Q2 Q4 Q2 Q2
revenue 1 770M 1 597M 1 663M 1 860M 1 543M 1 352M
costOfRevenue 1 080M 966M 1 043M 1 378M 965M 771M
grossProfit 690M 632M 620M 482M 578M 581M
grossProfitRatio 0.390 0.396 0.373 0.259 0.375 0.430
researchAndDevelopmentExpenses 114M 88M 87M -614M 85M 87M
generalAndAdministrativeExpenses 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 353M 300M 292M -820M 308M 250M
otherExpenses 0 0 0 926 000 -926 000 0
operatingExpenses 467M 389M 379M -1 433M 393M 337M
costAndExpenses 1 547M 1 354M 1 423M -55M 1 358M 1 108M
interestIncome 0 151M 97M -10M 9M 2M
interestExpense 91M 151M 139M -269M 128M 52M
depreciationAndAmortization 109M -65 000 -801 000 -151M -1M 85M
ebitda 332M 251M 253M -597M 264M 312M
ebitdaratio 0.187 0.157 0.152 -0.321 0.171 0.231
operatingIncome 223M 251M 254M -446M 265M 251M
operatingIncomeRatio 0.126 0.157 0.152 -0.240 0.172 0.185
totalOtherIncomeExpensesNet -146M 7M 12M 269M -120M -61M
incomeBeforeTax 77M 100M 113M -177M 146M 190M
incomeBeforeTaxRatio 0.043 0.062 0.068 -0.095 0.094 0.140
incomeTaxExpense 28M 6M 16M -110M 31M 38M
netIncome 56M 60M 60M -67M 90M 137M
netIncomeRatio 0.032 0.037 0.036 -0.036 0.059 0.101
eps 0.082 0.090 0.077 -0.098 0.130 0.200
epsdiluted 0.082 0.090 0.077 -0.098 0.130 0.200
weightedAverageShsOut 679M 679M 679M 680M 695M 684M
weightedAverageShsOutDil 679M 679M 679M 680M 695M 684M
link Link Link
finalLink Link Link

Balance Sheet Statement

Property 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q2 2021 q2
date 2023-12-31 2023-09-30 2023-06-30 2023-02-15 2022-12-31 2022-06-30 2021-06-30
symbol GRFS GRFS GRFS GRFS GRFS GRFS GRFS
reportedCurrency EUR EUR EUR USD USD EUR EUR
cik 1M 1M 1M 1M 1M 1M 1M
fillingDate 2024-04-19 2023-09-30 2023-06-30 2023-02-15 2023-04-18 2022-06-30 2021-06-30
acceptedDate 2024-04-19 16:30:06 2023-09-29 20:00:00 2023-06-30 00:00:00 2023-02-15 14:47:38 2023-04-18 09:25:44 2022-06-29 20:00:00 2021-06-29 20:00:00
calendarYear 2023.000 2023.000 2023.000 2023.000 2022.000 2022.000 2021.000
period Q4 Q3 Q2 Q1 Q4 Q2 Q2
cashAndCashEquivalents 530M 484M 523M 0 0 525M 398M
shortTermInvestments 116M 59M 34M 0 0 36M 10M
cashAndShortTermInvestments 530M 544M 557M 0 0 561M 408M
netReceivables 811M 908M 866M 0 0 773M 645M
inventory 3 459M 3 487M 3 317M 0 0 2 934M 2 124M
otherCurrentAssets 1 652M 77M 64M 0 0 165M 63M
totalCurrentAssets 6 452M 5 015M 4 805M 0 0 4 433M 3 240M
propertyPlantEquipmentNet 4 192M 3 279M 3 226M 0 0 4 228M 3 135M
goodwill 6 802M 0 6 899M 0 0 7 848M 5 989M
intangibleAssets 2 832M 10 876M 2 880M 0 0 1 737M 1 571M
goodwillAndIntangibleAssets 9 634M 10 876M 10 647M 0 0 9 585M 7 559M
longTermInvestments 703M 2 597M 2 536M 0 0 2 555M 2 137M
taxAssets 319M 0 219M 0 0 204M 142M
otherNonCurrentAssets 154M 297M 0 0 0 34M 0
totalNonCurrentAssets 15 003M 17 049M 16 628M 0 0 16 606M 12 974M
otherAssets 0 0 0 0 0 0 0
totalAssets 21 455M 22 064M 21 433M 0 0 21 039M 16 213M
accountPayables 813M 0 709M 0 0 701M 580M
shortTermDebt 898M 757M 733M 0 0 401M 900M
taxPayables 15M 0 29M 0 0 77M 30M
deferredRevenue 39M 0 -709M 0 0 0 0
otherCurrentLiabilities 565M 1 268M 1 144M 0 0 554M 412M
totalCurrentLiabilities 2 316M 2 025M 1 877M 0 0 1 656M 1 921M
longTermDebt 8 215M 10 299M 10 203M 0 0 9 155M 6 706M
deferredRevenueNonCurrent 14M 0 -1 003M 0 0 16M 17M
deferredTaxLiabilitiesNonCurrent 1 002M 0 1 003M 0 0 701M 580M
otherNonCurrentLiabilities 1 921M 1 171M 1 130M 0 0 9 861M 52M
totalNonCurrentLiabilities 11 153M 11 471M 11 332M 0 0 10 963M 7 354M
otherLiabilities 0 0 0 0 0 0 0
capitalLeaseObligations 1 004M 0 890M 0 0 1 071M 783M
totalLiabilities 13 468M 13 496M 13 209M 0 0 12 620M 9 276M
preferredStock 0 0 0 0 0 0 0
commonStock 120M 120M 1 030M 0 0 1 030M 1 030M
retainedEarnings 59M 3M -56M 0 0 144M 267M
accumulatedOtherComprehensiveIncomeLoss 4 950M 5 252M 5 046M 0 0 5 315M 4 035M
othertotalStockholdersEquity 699M 752M -159M 0 0 -159M -164M
totalStockholdersEquity 5 827M 6 127M 5 862M 0 0 6 330M 5 168M
totalEquity 7 972M 8 569M 8 224M 0 0 6 330M 5 168M
totalLiabilitiesAndStockholdersEquity 21 455M 22 064M 21 433M 0 0 18 950M 14 444M
minorityInterest 2 145M 2 442M 2 362M 0 0 0 0
totalLiabilitiesAndTotalEquity 21 455M 22 064M 21 433M 0 0 18 950M 14 444M
totalInvestments 703M 2 657M 2 570M 0 0 2 591M 2 147M
totalDebt 10 117M 11 057M 10 936M 0 0 9 556M 7 606M
netDebt 9 588M 10 572M 10 413M 0 0 9 031M 7 208M
link Link Link Link
finalLink Link Link Link

Cash Flow Statement

Property 2023 q4 2023 q3 2023 q2 2021 q2 2021 q1 2020 q4
date 2023-12-31 2023-09-30 2023-06-30 2021-06-30 2021-03-31 2020-12-31
symbol GRFS GRFS GRFS GRFS GRFS GRFS
reportedCurrency EUR EUR EUR EUR EUR EUR
cik 1M 1M 1M 1M 1M 1M
fillingDate 2024-04-19 2023-09-30 2023-06-30 2021-06-30 2021-03-31 2020-12-31
acceptedDate 2024-04-19 16:30:06 2023-09-29 20:00:00 2023-06-29 20:00:00 2021-06-30 00:00:00 2021-03-31 00:00:00 2020-12-30 19:00:00
calendarYear 2023.000 2023.000 2023.000 2021.000 2021.000 2020.000
period Q4 Q3 Q2 Q2 Q1 Q4
netIncome 56M 60M 52M 248M 130M 133M
depreciationAndAmortization 109M 107M 107M 85M 82M 82M
deferredIncomeTax 0 0 0 0 0 0
stockBasedCompensation 0 0 0 0 0 0
changeInWorkingCapital 45M -58M -115M -90M -89M -39M
accountsReceivables -5M 73M -60M 0 42M 0
inventory -88M -140M -55M 1M -67M -95M
accountsPayables 126M 26M 0 0 -64M 0
otherWorkingCapital 12M -16M 0 -92M 0 0
otherNonCashItems 130M 302M -86M -81M 55M 83M
netCashProvidedByOperatingActivities 156M 156M -42M 162M 178M 259M
investmentsInPropertyPlantAndEquipment -103M -66M -33M -73M -60M 0
acquisitionsNet 25M -51M 0 12M -505M -450M
purchasesOfInvestments -93M 23M 0 0 0 0
salesMaturitiesOfInvestments 15M -13M 0 0 0 0
otherInvestingActivites 15M -15M -17M 4M -3M -102M
netCashUsedForInvestingActivites -142M -123M -50M -56M -567M -552M
debtRepayment -150M -133M 0 0 0 0
commonStockIssued 0 0 0 0 0 0
commonStockRepurchased 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites 2M 2M 190M -84M 169M -133M
netCashUsedProvidedByFinancingActivities 46M -79M 190M -84M 169M -133M
effectOfForexChangesOnCash -16M 8M -135 000 -5M 22M -27M
netChangeInCash 45M -39M 98M 17M -199M -454M
cashAtEndOfPeriod 530M 484M 523M 398M 381M 580M
cashAtBeginningOfPeriod 484M 523M 426M 381M 580M 1 033M
operatingCashFlow 156M 156M -42M 162M 178M 259M
capitalExpenditure -103M -66M -33M -73M -60M -102M
freeCashFlow 53M 89M -75M 89M 118M 156M
link Link
finalLink Link

Earning call transcript

2023 q3
2023-11-02 ET (fiscal 2023 q3)
2023 q2
2023-07-27 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)

Press-releases

Show financial reports only

2024-02-14 08:16 ET
Grifols announces positive topline phase 3 fibrinogen clinical trial results
2024-01-09 17:36 ET
GRFS Alert: Monsey Law Firm of Wohl & Fruchter LLP Investigating Grifols, S.A. for Potential Securities Law Violations
2023-11-15 13:00 ET
Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency
2023-11-06 13:00 ET
GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023
2023-10-24 22:30 ET
Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD
2023-10-19 12:00 ET
GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum Neurotoxins
2023-09-28 12:00 ET
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
2023-08-01 12:00 ET
Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics
2023-07-20 12:15 ET
Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients
2023-07-18 12:00 ET
Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis
2023-07-13 12:00 ET
Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency
2023-05-11 12:30 ET
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD
2023-04-18 14:30 ET
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023
2023-03-06 12:00 ET
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
2022-11-03 13:00 ET
Grifols receives FDA clearance for AlphaID™ At Home, the first free service for U.S. consumers to determine their risk for alpha-1
2022-10-03 16:52 ET
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
2022-09-15 14:29 ET
GigaGen Awarded Contract by U.S. Department of Defense to Discover Synthetic Human Antibody Treatments for High-Priority Toxins and Pathogens
2022-09-07 16:06 ET
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
2022-05-19 15:39 ET
GigaGen Publishes Research Demonstrating the Potential of its Machine Learning Platform to Improve Antibody Drug Discovery and Development
2022-04-29 18:00 ET
Grifols 2021 Annual Report on Form 20-F filed with the SEC on April 29, 2022
2022-04-25 12:13 ET
Grifols completes the acquisition of Biotest: a strategic and transformational transaction to accelerate growth and innovation
2022-03-15 09:00 ET
Araclon Biotech advances in its innovative vaccine and diagnostic test for Alzheimer's
2022-03-02 14:00 ET
Grifols partners with Feeding America® to help address hunger in the U.S.
2022-02-24 11:00 ET
Grifols signs global collaboration and licensing agreement with Endpoint Health to develop and commercialize Antithrombin III for Sepsis
2022-02-09 14:00 ET
Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS,' extends category leadership for sixth consecutive year
2022-01-04 17:30 ET
Grifols acquires its first plasma donation center in Canada
2021-11-30 14:00 ET
Grifols reaches milestone with 300th U.S. plasma donor center, continuing to increase supply of urgently needed plasma
2021-11-04 13:00 ET
Grifols introduces ALBUTEIN FlexBag™ (Albumin [Human] U.S.P.) in 5% and 25% concentrations, a more convenient option for healthcare professionals
2021-10-19 15:18 ET
Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines
2021-08-11 14:26 ET
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19
2021-07-28 12:00 ET
Alkahest Strengthens Management Team with Addition of César Cerezo as Chief Medical Officer
2021-07-14 14:00 ET
GigaGen Publishes Research Describing Novel Mechanism of Action and Therapeutic Potential of its anti-CTLA-4 Drug Candidate, GIGA-564
2021-06-01 14:30 ET
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B
2021-05-25 14:15 ET
GigaGen Publishes Research Describing Potential New Avenues to Overcome Resistance to anti-PD-L1 Therapies
2021-05-19 09:30 ET
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona
2021-04-28 10:44 ET
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics
2021-04-15 15:59 ET
GigaGen Publishes Research on Company’s Recombinant Hyperimmunes in Nature Biotechnology
2021-04-15 13:00 ET
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030
2021-04-09 14:30 ET
Grifols 2020 Annual Report on Form 20-F filed with the SEC on April 9, 2021
2021-04-02 15:18 ET
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19
2021-03-23 14:00 ET
GigaGen to Present Poster at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting
2021-03-22 13:00 ET
Grifols installs first-ever DG Reader Net analyzer in North America
2021-03-09 08:15 ET
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins
2021-03-08 18:00 ET
Alkahest to Present Positive Data from Completed Phase 2 Clinical Trial at the 15th International Conference on Alzheimer’s and Parkinson’s Disease
2021-03-08 12:00 ET
Grifols fosters world's first scientific journal specialized in blood plasma
2021-02-23 14:00 ET
Grifols PharmacyKeeper ranked No. 1 as 'Best in KLAS' for fifth consecutive year
2021-01-28 13:00 ET
Alkahest Announces Peer-Reviewed Publication Demonstrating Safety and Tolerability of GRF6019 in Patients with Mild-to-Moderate Alzheimer’s Disease
2021-01-18 11:00 ET
Grifols begins clinical trial of a new treatment that would provide immediate immunity against COVID-19
2020-11-16 14:14 ET
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies
2020-11-12 14:00 ET
Grifols partners with TRC Healthcare to streamline intravenous compounding education
2020-10-09 10:23 ET
Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19
2020-10-01 16:13 ET
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.
2020-09-07 06:50 ET
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome
2020-07-28 14:41 ET
Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials
2020-07-27 17:18 ET
Results of Grifols' AMBAR clinical trial published in Alzheimer's & Dementia: The Journal of The Alzheimer's Association
2020-07-23 12:00 ET
Grifols acquires 10% stake in Bloodbuy, cloud-based marketplace for blood products
2020-07-20 06:39 ET
Grifols to acquire Green Cross plasma fractionation facility in Montreal and a plasma collection organization in the U.S. for US$460 million
2019-12-12 14:24 ET
Grifols launches XEMBIFY® (immune globulin subcutaneous human-klhw) 20%, a new Primary Immunodeficiency treatment
2019-12-06 20:42 ET
Grifols presents its latest Alzheimer's clinical trial data
2019-12-05 15:26 ET
Grifols Streamlines Hospital Pharmacy Operations With New KIRO Fill® Technology and PharmacyKeeper Enhancements
2019-12-02 14:17 ET
Grifols to present latest Alzheimer's clinical trial results
2019-11-07 15:00 ET
Grifols introduces AlphaID(TM), a free cheek swab to screen for Alpha-1, the most common genetic form of COPD
2019-10-17 09:00 ET
Grifols Procleix Panther System With Automation Ready Technology (ART) Receives CE-mark
2019-07-16 06:39 ET
Grifols presents additional encouraging Alzheimer's trial results at AAIC
2019-07-04 15:51 ET
Grifols Announces FDA Approval of Xembify®, 20% Subcutaneous Immunoglobulin for Primary Immunodeficiencies
2019-07-03 09:00 ET
Grifols Selected to Build Its First Intravenous Solutions Manufacturing Line in Africa
2019-06-19 13:00 ET
Grifols to launch plasma-protein-based bleeding-control solutions
2019-04-29 16:00 ET
Grifols Announces the Opening of its new Plasma Donor Center in Hinesville, Georgia
2019-04-18 13:00 ET
Grifols US donor centers exceed 250,000 pounds of food collected
2019-04-15 10:15 ET
Grifols donations of blood clotting factor helping people with hemophilia globally
2019-04-05 14:55 ET
Grifols 2018 Annual Report on Form 20-F Filed With the SEC on April 5, 2019

SEC forms

Show financial reports only

SEC form 6
2024-03-01 14:18 ET
Grifols published news for 2023 q4
SEC form 6
2024-03-01 14:12 ET
Grifols published news for 2023 q4
SEC form 6
2024-03-01 13:40 ET
Grifols published news for 2023 q4
SEC form 6
2024-02-29 15:23 ET
Grifols published news for 2023 q4
SEC form 6
2024-02-27 11:30 ET
Grifols published news for 2023 q4
SEC form 6
2024-02-20 09:23 ET
Grifols published news for 2023 q4
SEC form 6
2024-02-06 10:39 ET
Grifols published news for 2023 q4
SEC form 6
2024-02-05 14:35 ET
Grifols published news for 2023 q4
SEC form 6
2024-01-26 17:14 ET
Grifols published news for 2023 q4
SEC form 6
2024-01-16 06:05 ET
Grifols published news for 2023 q4
SEC form 6
2024-01-10 13:08 ET
Grifols published news for 2023 q4
SEC form 6
2024-01-10 08:59 ET
Grifols published news for 2023 q4
SEC form 6
2024-01-09 14:49 ET
Grifols published news for 2023 q4
SEC form 6
2024-01-09 08:25 ET
Grifols published news for 2023 q4
SEC form 6
2023-12-29 09:46 ET
Grifols published news for 2023 q3
SEC form 6
2023-12-29 09:40 ET
Grifols published news for 2023 q3
SEC form 6
2023-11-02 13:25 ET
Grifols published news for 2023 q3
SEC form 6
2023-10-20 08:36 ET
Grifols published news for 2023 q3
SEC form 6
2023-07-27 11:44 ET
Grifols published news for 2023 q2
SEC form 6
2023-06-20 07:12 ET
Grifols published news for 2023 q1
SEC form 6
2023-06-14 16:52 ET
Grifols published news for 2023 q1
SEC form 6
2023-04-18 09:25 ET
Grifols published news for 2023 q1
SEC form 6
2023-02-28 13:08 ET
Grifols published news for 2022 q4
SEC form 6
2023-02-24 12:23 ET
Grifols published news for 2022 q4
SEC form 6
2023-02-21 13:51 ET
Grifols published news for 2022 q4
SEC form 6
2023-02-15 14:47 ET
Grifols published news for 2022 q4
SEC form 6
2022-10-21 17:10 ET
Grifols published news for 2022 q3
SEC form 6
2022-10-03 17:26 ET
Grifols published news for 2022 q3
SEC form 6
2022-09-26 09:18 ET
Grifols published news for 2022 q2
SEC form 6
2022-09-07 13:38 ET
Grifols published news for 2022 q2
SEC form 6
2022-07-28 11:33 ET
Grifols published news for 2022 q2
SEC form 6
2022-07-28 11:03 ET
Grifols published news for 2022 q2
SEC form 6
2022-06-30 11:40 ET
Grifols published news for 2022 q1
SEC form 6
2022-06-13 06:01 ET
Grifols published news for 2022 q1
SEC form 6
2022-05-06 12:09 ET
Grifols published news for 2022 q1
SEC form 6
2022-04-29 12:15 ET
Grifols published news for 2022 q1
SEC form 6
2022-04-28 16:13 ET
Grifols published news for 2022 q1
SEC form 6
2022-04-25 09:41 ET
Grifols published news for 2022 q1
SEC form 6
2022-04-12 14:19 ET
Grifols published news for 2022 q1
SEC form 6
2022-02-28 13:22 ET
Grifols published news for 2021 q4
SEC form 6
2022-02-28 12:09 ET
Grifols published news for 2021 q4
SEC form 6
2021-11-17 06:57 ET
Grifols published news for 2021 q3
SEC form 6
2021-10-26 07:34 ET
Grifols published news for 2021 q3
SEC form 6
2021-10-05 11:56 ET
Grifols published news for 2021 q3
SEC form 6
2021-09-17 10:16 ET
Grifols published news for 2021 q2
SEC form 6
2021-09-17 06:25 ET
Grifols published news for 2021 q2
SEC form 6
2021-08-16 10:23 ET
Grifols published news for 2021 q2
SEC form 6
2021-08-09 06:02 ET
Grifols published news for 2021 q2
SEC form 6
2021-07-30 09:24 ET
Grifols published news for 2021 q2
SEC form 6
2021-07-30 06:01 ET
Grifols published news for 2021 q2
SEC form 6
2021-07-29 11:09 ET
Grifols published news for 2021 q2
SEC form 6
2021-06-30 07:33 ET
Grifols published news for 2021 q1
SEC form 6
2021-06-03 11:13 ET
Grifols published news for 2021 q1
SEC form 6
2021-06-01 08:55 ET
Grifols published news for 2021 q1
SEC form 6
2021-05-21 07:50 ET
Grifols published news for 2021 q1
SEC form 6
2021-05-04 07:28 ET
Grifols published news for 2021 q1
SEC form 6
2021-04-16 10:01 ET
Grifols published news for 2021 q1
SEC form 6
2021-04-09 09:26 ET
Grifols published news for 2021 q1
SEC form 6
2021-04-07 08:45 ET
Grifols published news for 2021 q1
SEC form 6
2021-03-12 06:00 ET
Grifols published news for 2020 q4
SEC form 6
2021-03-09 06:01 ET
Grifols published news for 2020 q4
SEC form 6
2021-03-01 08:18 ET
Grifols published news for 2020 q4
SEC form 6
2021-02-26 07:14 ET
Grifols published news for 2020 q4
SEC form 6
2021-02-22 07:00 ET
Grifols published news for 2020 q4
SEC form 6
2021-01-19 08:22 ET
Grifols published news for 2020 q4
SEC form 6
2020-12-16 11:01 ET
Grifols published news for 2020 q3
SEC form 6
2020-12-15 11:58 ET
Grifols published news for 2020 q3
SEC form 6
2020-11-24 09:03 ET
Grifols published news for 2020 q3
SEC form 6
2020-11-09 12:20 ET
Grifols published news for 2020 q3
SEC form 6
2020-11-05 06:59 ET
Grifols published news for 2020 q3
SEC form 6
2020-10-21 09:20 ET
Grifols published news for 2020 q3
SEC form 6
2020-10-09 08:14 ET
Grifols published news for 2020 q3
SEC form 6
2020-10-01 14:25 ET
Grifols published news for 2020 q3